- Home
- COOK vs PHAT Comparison
COOK vs PHAT Comparison
Compare COOK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- PHAT
- Stock Information
- Founded
- COOK 1985
- PHAT 2018
- Country
- COOK United States
- PHAT United States
- Employees
- COOK N/A
- PHAT N/A
- Industry
- COOK Wholesale Distributors
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- COOK Consumer Discretionary
- PHAT Health Care
- Exchange
- COOK Nasdaq
- PHAT Nasdaq
- Market Cap
- COOK 406.5M
- PHAT 465.0M
- IPO Year
- COOK 2021
- PHAT 2019
- Fundamental
- Price
- COOK $2.26
- PHAT $5.67
- Analyst Decision
- COOK Buy
- PHAT Strong Buy
- Analyst Count
- COOK 5
- PHAT 4
- Target Price
- COOK $4.10
- PHAT $23.00
- AVG Volume (30 Days)
- COOK 115.0K
- PHAT 1.0M
- Earning Date
- COOK 03-06-2025
- PHAT 03-06-2025
- Dividend Yield
- COOK N/A
- PHAT N/A
- EPS Growth
- COOK N/A
- PHAT N/A
- EPS
- COOK N/A
- PHAT N/A
- Revenue
- COOK $598,914,000.00
- PHAT $26,270,000.00
- Revenue This Year
- COOK $1.02
- PHAT $7,453.23
- Revenue Next Year
- COOK $4.69
- PHAT $226.38
- P/E Ratio
- COOK N/A
- PHAT N/A
- Revenue Growth
- COOK 3.17
- PHAT N/A
- 52 Week Low
- COOK $1.97
- PHAT $5.21
- 52 Week High
- COOK $3.97
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- COOK 34.08
- PHAT 39.59
- Support Level
- COOK $2.37
- PHAT $5.50
- Resistance Level
- COOK $2.52
- PHAT $6.21
- Average True Range (ATR)
- COOK 0.09
- PHAT 0.40
- MACD
- COOK -0.01
- PHAT 0.07
- Stochastic Oscillator
- COOK 14.56
- PHAT 38.69
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.